
How To Embrace Neurodiversity In The Workplace To Improve Innovation
Neurodiversity means there is no single "correct" way for the brain to work. The reality is that the workplace includes people who have a wide range of conditions, including autism spectrum disorder, ADHD, dyslexia, and learning disabilities. Research has found that 19% of Americans identify as neurodivergent. Neurodiverse individuals can bring "fresh eyes" to problems. Their unique ways of thinking are valuable because employees often get stuck in doing things the way they have always done them. When you bring in someone who has a unique perspective or has not been influenced by status-quo thinking, that is when the best ideas can happen. When individuals stay focused, question routines, and bring original thinking that challenges assumptions, it creates innovative ideas. Sometimes these thinkers go unnoticed, or worse, ignored. But when leaders start paying attention to how people solve problems, that is when their teams adapt faster, think more clearly, and produce stronger results.
How Can Neurodiversity In The Workplace Improve Problem-Solving?
How Can Neurodiversity In The Workplace Improve Problem-Solving?
When team members think differently, they often notice things that others miss. This is especially true when facing complex challenges that have no clear solution. A Deloitte study found that teams including neurodivergent talent outperformed others on tasks requiring creativity, accuracy, and pattern recognition. These thinkers tend to spot gaps in logic, inconsistencies in data, or errors in execution before anyone else does.
Some companies have started to see how problem-solving improves when diverse minds are involved from the beginning. SAP's Autism at Work program led to measurable increases in productivity across several teams. They noticed that when neurodivergent employees were hired and supported properly, their ways of working led to better questions, deeper analysis, and clearer workflows.
Fresh ideas often come from people who have not been conditioned to accept what everyone else accepts. Neurodivergent individuals often bring that perspective because they experience the world differently.
What Makes Neurodiversity In The Workplace Difficult To Manage?
What Makes Neurodiversity In The Workplace Difficult To Manage?
Leaders often say they support inclusion, but they sometimes overlook what inclusion really involves. Neurodiversity introduces differences in communication, work rhythms, and ways of processing information. These differences can be misunderstood as performance issues when the real issue is a mismatch between the environment and the person's strengths.
Many neurodivergent professionals report that unspoken rules are the hardest part of working in a traditional office. If someone needs more time to respond, prefers written instructions, or skips small talk, they may be misjudged as uncooperative or disengaged. But when managers get specific about goals and outcomes, they start to see that these same employees often produce more consistent, high-quality results than expected.
The mistake is assuming one communication style or workflow suits everyone. That assumption limits potential and often leads to disengagement. When leaders ask questions instead of making assumptions, they open the door to understanding how to bring out the best in each person.
What Should Leaders Do To Support Neurodiversity In The Workplace?
What Should Leaders Do To Support Neurodiversity In The Workplace?
Support starts with curiosity and the willingness to meet people where they are. A simple question like 'How can I help you do your best work?' can lead to a breakthrough. That question signals that differences are respected.
Many of the adjustments that help neurodivergent employees—like using clear written communication, offering flexible deadlines, or minimizing background noise—benefit everyone. Instead of singling people out, this designs work in a way that supports how the brain functions under pressure.
There are also cultural shifts that leaders can make. Try having meetings that include time for reflection, allow written follow-ups instead of immediate responses, and avoid fast-paced brainstorming where only the loudest voices are heard. These changes can increase inclusion without compromising results.
How Does Neurodiversity In The Workplace Increase Innovation?
How Does Neurodiversity In The Workplace Increase Innovation?
Innovation grows in teams that welcome mental friction. Not the kind that creates conflict, but the kind that invites different patterns of thinking. Neurodivergent individuals are often the ones who explore ideas that seem unconventional.
This kind of focus is especially valuable in roles that require deep concentration or attention to detail. For example, JPMorgan Chase launched a program to recruit autistic talent for quality assurance and cybersecurity roles. They reported higher productivity, lower error rates, and greater retention in those roles compared to traditional hires. These outcomes came from giving employees the freedom to approach their work in the way that suited them best.
How Can You Build A Workplace That Embraces Neurodiversity Starting This Week?
How Can You Build A Workplace That Embraces Neurodiversity Starting This Week?
You can start building a workplace that embraces neurodiversity by using both written and verbal communication. After meetings or assignments, follow up with a quick written summary. It helps those who process information more slowly and makes instructions easier to refer back to.
Ask about preferred work styles. Not everyone works best under pressure or in noisy environments. Some thrive on routines, while others need more autonomy. Listen when people tell you what works for them.
Using vague terms like 'be more engaged' or 'speak up more' is not helpful. Be specific and focus on the quality of their contributions.
Why Neurodiversity In The Workplace Deserves More Attention Now
Why Neurodiversity In The Workplace Deserves More Attention Now
As jobs become more complex, companies will need to create space for different types of minds to thrive. The goal is to recognize that these individuals often hold the key to better outcomes. Neurodiversity already exists in your organization. The question is whether these people's strengths are being seen, heard, and supported. When organizations build a culture that embraces curiosity, they begin asking better questions about support, performance, and leadership. In that process, they often discover that some of their most overlooked employees may also be their most innovative.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Citi Maintains Neutral Rating on Simon Property Group (SPG)
Simon Property Group, Inc. (NYSE:SPG) is one of the most undervalued stocks. On June 17, Citi trimmed its price target on SPG from $185 to $170 while reiterating a Neutral rating on the stock. The company adjusted its 2025 funds from operations (FFO) estimate downward to $12.21 from the previous $12.52, adding the impact of Q1 results that included one-time expenses and investment losses of $0.28 per share. Similarly, Citi revised its 2025 core FFO forecast to $12.49, a slight decrease from $12.52, mainly driven by more conservative projections for net operating income. A rooftop view of a bustling downtown area, emphasizing the company's investments in the real estate sector. The updated price target implies a valuation multiple of approximately 14x the expected 2025 core FFO, down from the earlier multiple of around 15x. Citi attributed this multiple compression to increased uncertainty regarding potential tariff impacts and the overall creditworthiness of tenants. This adjustment in price target stems from Simon's recent earnings performance and denotes a conservative outlook on the retail property market amid broader economic headwinds. Simon Property Group, Inc. (NYSE:SPG) is a self-managed and self-administered REIT specializing in the ownership, development, and operation of premier retail and mixed-use properties, including malls, outlets, and international destinations. While we acknowledge the potential of SPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Truist Lifts COPT Defense Properties (CDP) PT to $30
COPT Defense Properties (NYSE:CDP) is one of the most undervalued stocks. On June 10, Truist maintained a Hold rating on CDP and raised the price target from $29 to $30. With a robust 4.31% yield, the company has consistently paid dividends for the past 34 years, indicating its commitment to shareholder returns. The target price update reflects a refined valuation approach that involves discounted cash flow analysis along with forecasted net asset value. Analysts reported that COPT Defense Properties (NYSE:CDP) is advancing three developments set to launch in 2025, with more projects on deck for 2026 and 2027. The $308 million active portfolio is 62% pre-leased, with 30% of the costs already invested. Occupancy at COPT Defense is forecasted to dip slightly to 91.9% by the end of 2025, compared to 92.3% in the first quarter. The firm also projects a low single-digit positive increase in GAAP rental spreads. A security guard patrolling a defense facility, protecting critical technologies. Analysts indicate that COPT Defense Properties (NYSE:CDP) is unlikely to engage in any mergers, acquisitions, or property disposals in 2025. However, they are factoring in a $400 million unsecured note issuance for the fourth quarter. COPT Defense, a self-managed REIT, focuses on the ownership, operation, and development of mission-critical real estate assets located near or within major US Government defense installations. While we acknowledge the potential of CDP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
UnitedHealth Stock Is One of the Worst-Performing S&P 500 Stocks in 2025. Should You Buy the Dip?
Wall Street is cheering fresh highs as the S&P 500 Index ($SPX) wraps a solid second quarter, closing June 2025 strong. The rally has been powered by cooling inflation, resilient earnings, and fading tariff concerns after April's policy shock. Just three months back, the market briefly dipped toward bear territory amid geopolitical tensions, China's AI push, tariff fears, and fiscal uncertainty, keeping investors on edge about the rebound's staying power. Despite the S&P rallying over 28% from its April lows of $4,835, the bull run has still left many big names behind. Nearly a third of the index's stocks still ended the first half of 2025 in the red. UnitedHealth (UNH), a giant in health insurance and managed care services, has plunged 39% so far in 2025. UNH stock has been hit by soaring Medicare Advantage costs, a probe into Medicare fraud, and a sudden CEO exit, making it the index's fourth-worst performer. Michael Saylor Says 'You'll Wish You'd Bought More' Bitcoin as MicroStrategy Doubles Down Is Microsoft Stock About to Go Nuclear? Is Super Micro Computer Stock a Buy, Sell, or Hold for July 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! While UNH is at five-year lows, a 1.8% five-day bounce hints at some life. With the dividend-paying stock halved and trading at a compelling valuation, is this a classic 'buy the dip' setup? Or a moment for caution despite the allure of value and yield? Founded in 1977, UnitedHealth has grown into a $295 billion healthcare heavyweight. With its deep roots in health insurance and care services, the company runs on two powerhouse engines: UnitedHealthcare and Optum. UnitedHealthcare handles the insurance side, offering plans that serve over 50 million people. It's the backbone, giving the company scale, reach, and reliable revenue. But it's Optum that brings the spark, driving growth through data, tech, and pharmacy solutions. From analytics to care delivery, Optum's strategy pushes innovation across the system. Together, these segments give the company its edge in a complex healthcare landscape. UNH stock has been in free fall in 2025, hitting a low of $248.88 in May. Over the past 52 weeks, the stock has declined 38%, trailing far behind the broader S&P's surge of 13%. However, UNH stock is rebounding, up 1% over the past month. UnitedHealth's downfall in 2025 was not just a single bad headline. It was a chain reaction that started fast and spiraled hard. It kicked off on April 17, when the company shocked the Street by slashing its full-year earnings forecast. This was because a flood of higher-acuity Medicare Advantage patients drove costs far beyond expectations, exposing just how outdated and fragile their forecasting models had become. Then May hit like a wrecking ball. CEO Andrew Witty abruptly resigned, raising eyebrows amid growing pressure. Days later, reports surfaced of a U.S. Department of Justice investigation into alleged Medicare fraud. By mid-May, the stock had crashed, hitting five-year lows. Just when it seemed the damage was done, more scandal dropped with accusations of UnitedHealth secretly paying nursing homes to avoid costly hospital transfers. Even insider buying gave only a brief lift to UNH. In a short span, UnitedHealth went from a rock-solid name to a cautionary tale unraveling in real time. After its brutal springtime plunge, UNH stock is priced at 14 times forward earnings and 0.7 times sales, trading in bargain territory. Those multiples sit well below both the sector medians and its own five-year averages, catching the eye of value hunters sniffing out a possible rebound. Despite the stock's decline, UnitedHealth has signaled some confidence where it counts: dividends. In June, the company hiked its quarterly payout by 5.2% to $2.21, marking 15 consecutive years of increases. Paid out on June 24, the hike pushed its annual yield near 2.6%. On April 17, UnitedHealth reported Q1 2025 earnings, and it wasn't the kind of update Wall Street wanted to hear. Revenue climbed 9.8% year-over-year (YOY) to $109.6 billion but still came in shy of expectations. Adjusted EPS rose 4.2% to $7.20 yet missed the estimated mark of $7.27. UnitedHealthcare, the insurance arm, posted a solid 12.2% revenue gain to $84.6 billion. Meanwhile, Optum saw more modest growth of 4.6% to $63.9 billion, with Optum Rx doing the heavy lifting. Still, rising costs loomed large. Total operating expenses surged 9.4% annually to $100.5 billion. On the brighter side, the company exited the quarter with $34.3 billion in cash and short-term investments and generated $5.5 billion in operating cash flow. Shareholders weren't left in the cold either, with over $5 billion returned through buybacks and dividends. UnitedHealth's steep selloff wasn't just about Q1 results. It was the guidance cut that really rattled sentiment. Management slashed its 2025 adjusted EPS outlook to between $26 and $26.50, down from the initially forecast range of $29.50 to $30 in December 2024 and below fiscal 2024 adjusted EPS of $27.66. Surging Medicare Advantage costs and shifts in Optum's patient mix have taken a real bite. Now, all eyes are on the fiscal Q2 report, expected to be released on July 29 before the market opens. Analysts forecast the Q2 bottom line to be around $5.08 per share, down 25% YOY. Looking to fiscal 2025, adjusted EPS is expected to decline 20% annually to $22.07, then surge by 15% to $25.39 in fiscal 2026. Last Wednesday, UBS reiterated its 'Buy' rating on UNH stock but trimmed the price target to $385 from $400. The cut followed CEO Stephen Hemsley's cautious tone at the June 2 meeting, hinting at more conservative 2025 guidance. UBS anticipates fiscal 2025 EPS closer to $20, down from the earlier $22.50 consensus. Margins were also revised, with Medicare Advantage trimmed to 1.5% and Optum Health lowered to 4.5%. Despite the recent shakeups, Wall Street hasn't completely hit the panic button yet. Last month, UnitedHealth shook things up by axing broker commissions on select Medicare Advantage plans — a move aimed at trimming the cost that forced it to yank full-year guidance. Hightower Chief Investment Strategist Stephanie Link called it a smart pivot, saying the same issue 'got them in trouble' to begin with. Link is bracing for short-term volatility but stays bullish long-term, calling UNH stock 'too cheap' for a top-tier name in the industry. There's still optimism in the air, but with a touch of caution. UNH stock has a 'Moderate Buy' consensus overall, down from a consensus 'Strong Buy' rating a month ago. Of the 24 analysts covering the stock, 15 advise a 'Strong Buy,' two suggest a 'Moderate Buy,' and seven analysts play it safe with a 'Hold.' The mean price target of $363.43 implies shares could rise as much as 18%. The Street-high target of $440, way below this year's highs, signals that UNH has an upside potential of 43% from current levels. The U.S. healthcare industry, despite constant political firestorms, is built to endure. For years, UnitedHealth has stood as its crown jewel. Defensive, dividend-paying, and shock-resistant, it has been the kind of stock long-term investors can count on. But 2025 has shattered that illusion. While the broader market climbs to record highs, UnitedHealth's dramatic plunge reminds us that even giants can stumble hard. Sure, UNH stock now trades at a discount, offering an attractive dividend yield. Insiders are buying shares, and UnitedHealth still commands significant market share and robust cash flow. But is this really a 'buy the dip' moment? It's probably a bet that management can steady the ship, and the storm eventually clears. Until then, UnitedHealth sits in a gray zone between legacy and uncertainty, where long-term promise collides with short-term pain. Investors should exercise caution before jumping in. On the date of publication, Sristi Suman Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data